Puretech Health PLC (LON:PRTC) insider Robert Langer bought 4,300 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were acquired at an average price of GBX 162 ($2.24) per share, for a total transaction of £6,966 ($9,624.21).
Shares of Puretech Health PLC (LON:PRTC) opened at GBX 164.30 ($2.27) on Wednesday. Puretech Health PLC has a twelve month low of GBX 110 ($1.52) and a twelve month high of GBX 183.50 ($2.54). The firm has a market cap of $388.58 and a P/E ratio of -864.74.
PRTC has been the subject of a number of recent analyst reports. Peel Hunt upped their price target on shares of Puretech Health from GBX 302 ($4.17) to GBX 313 ($4.32) and gave the stock a “buy” rating in a report on Friday, January 26th. Jefferies Group reaffirmed a “buy” rating on shares of Puretech Health in a report on Friday, November 17th. Liberum Capital reaffirmed a “buy” rating and set a GBX 248 ($3.43) price target on shares of Puretech Health in a report on Friday, January 26th. Finally, Numis Securities reaffirmed a “buy” rating and set a GBX 259 ($3.58) price target on shares of Puretech Health in a report on Tuesday, February 20th. Five analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of GBX 260.20 ($3.59).
About Puretech Health
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.